Biohaven (BHVN) Cash & Equivalents (2021 - 2026)

Biohaven (BHVN) has 6 years of Cash & Equivalents data on file, last reported at $273.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 177.47% year-over-year to $273.1 million; the trailing twelve-month figure through Mar 2026 stood at $273.1 million (up 177.47% YoY), and the FY2025 full-year result was $230.0 million, up 131.97% from the prior year.
• Cash & Equivalents climbed to $273.1 million in Q1 2026, from $230.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $273.1 million in Q1 2026 to a low of $23.2 million in Q2 2022.
• A 5-year average of $147.6 million and a median of $147.6 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 85.99% in 2022 and jumped 536.01% in 2023, its largest moves.
• Tracing BHVN's Cash & Equivalents over 5 years: stood at $204.9 million in 2022, then rose by 21.24% to $248.4 million in 2023, then plunged by 60.09% to $99.1 million in 2024, then surged by 131.97% to $230.0 million in 2025, then increased by 18.75% to $273.1 million in 2026.
• Business Quant data shows BHVN's Cash & Equivalents at $273.1 million in Q1 2026, $230.0 million in Q4 2025, and $184.8 million in Q3 2025.